# The Patient Perspective and Value Assessment: Easy to Identify the Need, Hard to Agree on the Solution

ISPOR 23<sup>rd</sup> Annual International Meeting Baltimore, MD

May 23, 2018





# Value assessment frameworks need to reflect patient perspectives, but how?

- Condition-specific approaches
  - Allow attribute importance to vary across conditions
- Multiple perspectives
  - Distinguish groups per condition
- Predict preferences
  - Identify characteristics that reveal preferences





## **Author acknowledgement**

### llene Hollin, PhD MPH

Health Policy Fellow, National Pharmaceutical Council and University of Southern California Schaeffer Center for Health Policy and Economics

#### Mike Ciarametaro, MBA

Vice President of Research, National Pharmaceutical Council

#### Juan-Marcos Gonzalez, PhD

Assistant Professor in Population Health Sciences, Duke University School of Medicine

#### Robert Morlock, PhD

Managing Director, YourCareChoice





## Surveyed 500+ patients/caregivers on value as a function of 7 attributes

Attribute	# of levels
Survival	5
Functioning	4
Side effects	4
Treatment requirements	4
Out-of-pocket costs	4
Insurance company costs	4
Available test to see if therapy will work	2



Patients: rheumatoid arthritis (n=101); hypertension (n=100); breast cancer (n=100) Schaeffer Caregivers: pediatric asthma (n=101); Alzheimer's disease (n=101)



## Sample choice task

Scenario 1 of 12	Therapy 1	Therapy 2	Therapy 3	
Average <u>life extension</u> due to reduction in risk of heart attack or stroke compared to current therapy	9 months	12 months	No improvement	
Average improvement in your functioning due to less pain and joint swelling compared to current therapy	60% better	40% better	20% better	
Average change in <u>side effects</u> compared to current therapy	10% more major side effects 20% more minor side effects	회장 경영하는 경험이 되었다면 그 그리는 그렇게 되었다고 다른 경우 (경영) 되었다.		
Treatment requirements	infusion every 4 weeks	Injection every week	Oral daily \$100 per month \$25,000 per year  No test available to determine if the will work for you	
Your monthly <u>out-of-pocket costs</u>	\$25 per morth	\$2,000 per month		
Annual insurance company costs	\$40,000 per year	\$90,000 per year		
Asailable test to see if the therapy will work for you	No test available to determine if this will work for you	Test available and it indicates the therapy will work for you		
Which of the three therapy options do you most prefer?	() Therapy 1	O Therapy 2	O Therapy 3	
Would you switch from your current therapy to the therapy option you just selected if this therapy were available today?		○ No ○ Yes		

# Analytic methods detected groups that differed by preferences

- Latent class analysis
  - Verified appropriate number of groups
  - Results: preferences for each group
- Logistic regression
  - Results: estimates for predictors of groupmembership





# Group preferences differed for some attributes, not for others

	# of Groups	Survival	Functioning	Side effects	Treatment requirements	Out-of- pocket cost	Total cost	Test available
RA	2			#		#		
НТ	2			<b>≠</b>		#		=
ВС	2				#	#		#
PA	3	#	#	#		-		_
AD	2					#		



#### Legend:


RA = rheumatoid arthritis; HT=hypertension; BC = breast cancer; PA = pediatric asthma; AD=Alzheimer's disease







## Few predictors of preference groups found



# Value assessment frameworks need to reflect patient perspectives, but how?

- Condition-specific approaches
  - Allow attribute importance to vary across conditions
- Multiple perspectives
  - Distinguish groups per condition
- Predict preferences
  - Identify characteristics that reveal preferences





## How to make it a reality for framework development

- Ascertain what patients care about from the outset
- Identify conditions with sub-groups
- Determine if differences result in different decisions
- Test methods for incorporating preferences into value assessment frameworks
  - Weighting methodology
  - Expanded set of indirect benefits
- Distribute responsibility

Schaeffer

 Value framework developers, industry, patient advocate groups, researchers

